Kairos Pharma LtdNYSE American:KAPA
- LAST PRICE1.3300
- TODAY'S CHANGE (%)-0.0300 (-2.2059%)
- Bid / Lots1.2600/ 3
- Ask / Lots1.3900/ 1
- Open / Previous Close1.3200 / 1.3600
- Day Range
- 52 Week Range
- Volume51,058
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | KAPA |
|---|---|---|
| 09:32 ET | 833 | 1.3 |
| 09:38 ET | 100 | 1.25 |
| 09:41 ET | 9471 | 1.2699 |
| 09:43 ET | 200 | 1.2672 |
| 09:48 ET | 1850 | 1.2699 |
| 09:50 ET | 2627 | 1.24 |
| 09:52 ET | 21694 | 1.28 |
| 09:54 ET | 1259 | 1.32 |
| 09:56 ET | 4992 | 1.3099 |
| 09:59 ET | 1200 | 1.36 |
| 10:01 ET | 2501 | 1.33 |
Sep 24, 2024
Sep 17, 2024
Kairos Pharma Closing of $6.2 Million Initial Public Offering, from 4:29PM ET on Tuesday Sep 17, 2024 by Dow Jones
4:29PM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 16, 2024
DJ Kairos Pharma Shares Drop in First Trading Day, from 1:40PM ET on Monday Sep 16, 2024 by Dow Jones
1:40PM ET on Monday Sep 16, 2024 by Dow JonesKairos Pharma Prices $6.2 Million Initial Public Offering, from 10:49AM ET on Monday Sep 16, 2024 by Dow Jones
10:49AM ET on Monday Sep 16, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kairos Pharma Ltd | 17.5M | -8.5x | --- |
Cocrystal Pharma Inc | 17.4M | -1.0x | --- |
NRX Pharmaceuticals Inc | 17.3M | -1.0x | --- |
Mira Pharmaceuticals Inc | 17.6M | -1.4x | --- |
Cognition Therapeutics Inc | 17.7M | -0.5x | --- |
Athira Pharma Inc | 17.3M | -0.1x | --- |
Company Information
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its products consist of five pre-clinical or clinical-trial stage drug candidates developed by it and designed to target immune response, and two therapeutic agents developed by its Enviro Therapeutics, Inc. (Enviro) subsidiary and designed to increase anti-tumor response in conjunction with cancer therapies by addressing resistance to these agents. Its product portfolio includes a variety of technologies licensed by its Enviro subsidiary and consists of compositions and methods for treating diseases and conditions by targeting CD105 and depleting mitochondrial DNA from the circulation. Its products include KROS 101, 102, 201, 301, 401, ENV 105 and 205.
Contact Information
- Headquarters
- 2355 Westwood Blvd. #139LOS ANGELES, CA, United States 90064
- Phone
- 818-404-5541
- Fax
- 845-818-3588
Executives
- Chairman of the Board, Chief Executive Officer
- John Yu
- Chief Financial Officer
- Douglas Samuelson
- Chief Scientific Officer
- Neil Bhowmick
- Vice President - Research & Development
- Ramachandran Murali
- Independent Director
- Hyun Bae
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 12.8M |
Kairos Pharma Ltd does not pay a dividend. | |
Beta | --- |
EPS | $-0.16 |
Book Value | $-0.16 |
P/E Ratio | -8.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
